No Data
Huaren Pharmaceutical (300110.SZ): The application notification letter for the上市 for hydrochloride deoxyephedrine Active Pharmaceutical Ingredient has been approved.
Huaren Pharmaceutical (300110.SZ) announced that recently, the company's wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. (abbreviated as...
The Five-year Underlying Earnings Growth at Huaren Pharmaceutical (SZSE:300110) Is Promising, but the Shareholders Are Still in the Red Over That Time
Huaren Pharmaceutical: 2024 Annual Results Forecast
Huaren Pharmaceutical (300110.SZ): The Active Pharmaceutical Ingredient for perphenazine has received a notification of approval for its listing application.
On January 21, Glonghui reported that Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. received the "Chemical Raw Materials Approval Notice" issued by the National Medical Products Administration for the "Pirfenidone Active Pharmaceutical Ingredient". Pirfenidone is indicated for idiopathic pulmonary interstitial fibrosis. According to statistics from Yaozhi Network, the domestic consumption of Pirfenidone Active Pharmaceutical Ingredient in 2023 was 6.14 tons, an increase of 25.05% year-on-year.
Huaren Pharmaceutical (300110.SZ) subsidiary has obtained a medical instruments registration certificate.
Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd. received a notification from ShanDong...
Huaren Pharmaceutical (300110.SZ): Termination of the president position of Hong Liang.
On December 27, Glonghui reported that Huaren Pharmaceutical (300110.SZ) announced the convening of the sixth (extraordinary) meeting of the eighth Board of Directors on December 27, 2024, which reviewed and approved the "Proposal for the Dismissal of the Company's Chief Executive Officer." According to the needs of the company's Operation management, after the review by the Board of Directors' Nomination Committee, the Board of Directors agreed to dismiss Mr. Hong Liang from the position of Chief Executive Officer, with the dismissal taking effect from the date of approval by this Board of Directors meeting. Following the dismissal, Mr. Hong Liang will no longer hold any position within the company, and this dismissal will not adversely affect the normal operation of the company's daily production and Operation activities.
Investors Give Huaren Pharmaceutical Co., Ltd. (SZSE:300110) Shares A 30% Hiding